- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
ANDA Litigation Settlements
Fall 2015
Case Name | Drug | Patent No(s). | Publicly Available Terms |
---|---|---|---|
Forest Labs., Inc. v. Amneal Pharms. LLC, 15-0508 (D. Del.) |
Namenda XR® (memantine hydrochloride) |
5,061,703 |
Subject to FTC review, plaintiffs will grant Amneal a license to market generic versions of Namenda XR beginning on Jan. 31, 2020, following receipt by Amneal of final approval from the FDA. Alternatively, under certain circumstances, Amneal has an option to launch an authorized generic version of Namenda XR beginning on Jan. 31, 2021. |
United Therapeutics Corp. v. Sandoz Inc., 12-1617, 13-0316 (D.N.J.) |
Remodulin® (treprostinil sodium injection) |
6,765,117 |
United Therapeutics Corp. grants Sandoz a non-exclusive license to manufacture and sell generic Remodulin starting June 26, 2018, and perhaps sooner under certain circumstances. Both parties drop their respective pending appeals and a separate patent lawsuit over the process for preparing treprostinil sodium. The FTC and U.S. DOJ will review the agreement. |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.